When was SomaGenics founded?

SomaGenics was founded in 1997 and raised its 1st funding round 10 years after it was founded.

Where is SomaGenics located?

SomaGenics is headquartered in Santa Cruz, United States. It is registered at Santa Cruz,California.

How many employees does SomaGenics have?

As of Dec 31, 2022, the latest employee count at SomaGenics is 5.

Is SomaGenics a funded company?

SomaGenics is a funded company, having raised an undisclosed amount across 21 funding rounds to date. The company's 1st funding round was a $***** Grant (prize money) round, raised on May 15, 2007.

When was the latest funding round of SomaGenics?

SomaGenics' latest funding was a $***** Grant (prize money) round on Dec 05, 2019, with participation from 1 investor.

Where does SomaGenics rank among its competitors?

SomaGenics ranks 303rd amongst 601 active competitors, of which 226 are funded.

Who are the top competitors of SomaGenics?

SomaGenics' top competitors include BridgeBio, Spark Therapeutics and Exact Sciences. Among them, SomaGenics secured the most recent funding round in December, 2019.

SomaGenics - 2026 Company Profile, Team, Funding & Competitors

SomaGenics is a funded company based in Santa Cruz (United States), founded in 1997 by Brian Johnston. It operates as a Developer of RNA-based therapeutics and diagnosis for multiple disease conditions. SomaGenics has raised an undisclosed amount in funding. The company has 601 active competitors, including 226 funded and 140 that have exited. Its top competitors include companies like BridgeBio, Spark Therapeutics and Exact Sciences.

Company Details

Developer of RNA-based therapeutics and diagnosis for multiple disease conditions. The company's technology platforms include resQ-RNA technology for quantitative real-time PCR of fragmented RNA samples, miR-Direct, a method for multiplex detection of circulating microRNAs directly from serum or plasma, and miR-ACS, for construction of improved next-generation sequencing libraries. The company's therapeutic platform includes small synthetic shRNA (sshRNA) candidates to accelerate the healing of chronic wounds in diabetic patients and against Hepatitis delta virus (HDV) infections.

Website: somagenics.com
Email ID: *****@somagenics.com
Registered Address: Santa Cruz,California

Key Metrics

Founded Year

1997

Location

Santa Cruz, United States

Stage

Funding Raised

Latest Funding Round

Grant (prize money), Dec 05, 2019, $*****

Investors

NIH & 1 more

Ranked

303^rd among 601 active competitors

Employee Count

5 as on Dec 31, 2022

Similar Companies

BridgeBio & 745 more

View SomaGenics' full profile

SomaGenics is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Somagenics Inc CIN: 770462830 , United States, Active	Dec 31, 1999	-	5 (As on Dec 31, 2022)	-

SomaGenics has raised funding over 21 rounds. Its first funding round was on May 15, 2007. Its latest funding round was a Grant (prize money) round on Dec 05, 2019 for $*****. 1 investor participated in its latest round. SomaGenics has 2 institutional investors.

Here is the list of recent funding rounds of SomaGenics:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Dec 05, 2019	8074057	Grant (prize money)	6674104	8388381	9156995	7363701
Sep 01, 2019	3147580	Grant (prize money)	3390089	7591522	3317816	HHS
Jul 10, 2017	3622999	Grant (prize money)	7255221	2894674	2942503	HHS

Access funding benchmarks and valuations. Sign up today!

View details of SomaGenics's funding rounds and investors

The founders of SomaGenics is Brian Johnston.

Here are the details of SomaGenics' key team members:

Brian Johnston: Founder & CEO of SomaGenics.

View details of SomaGenics's Founder profiles and Board Members

SomaGenics' employee count trend

SomaGenics has 5 employees as of Dec 22. The total employee count is 17.0% lower than what it was in Dec 21. Here is SomaGenics's employee count trend over the years:

Uncover SomaGenics' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of SomaGenics include BridgeBio, Spark Therapeutics and Exact Sciences. Here is the list of Top 10 competitors of SomaGenics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	BridgeBio 2015, Palo Alto (United States), Acquired	Developer of therapeutics for the treatment of genetic diseases	$434M	KKR, Viking Global Investors & 20 others	75/100
2nd	Spark Therapeutics 2013, Philadelphia (United States), Acquired	Developer of gene therapy for rare diseases	$82.8M	Sofinnova Investments, LanceBio Ventures & 6 others	75/100
3rd	Exact Sciences 1995, Madison (United States), Public	Provider of non-invasive molecular diagnostic testing solutions for cancer	-	Great Point Partners, Bank of America & 8 others	73/100
4th	Forge Biologics 2020, Columbus (United States), Acquired	Developer of gene therapeutic solutions for treating multiple diseases	$330M	Aisling Capital, RA Capital Management & 7 others	72/100
5th	Fulcrum Therapeutics 2015, Cambridge (United States), Public	Developing small molecules for control mechanisms and genes regulation for the treatment of rare diseases	$115M	Foresite Capital, Third Rock Ventures & 15 others	72/100
6th	Strand Therapeutics 2017, Cambridge (United States), Series B	Provider of platform to deliver mRNA therapeutics for multi functional treatments	$256M	FPV Ventures, Kinnevik & 19 others	72/100
7th	Insitro 2018, San Francisco (United States), Series C	Developer of an AI-enabled technology platform for the treatment of infectious disease	$643M	Andreessen Horowitz, Foresite Capital & 18 others	72/100
8th	Alnylam 2002, Cambridge (United States), Public	Developer of RNA interference-based therapeutics for multiple disorders	$17M	Ridgeback Capital Management, BB Biotech ... & 13 others	71/100
9th	Generation Bio 2016, Cambridge (United States), Public	Developer of gene therapies for rare liver and eye diseases	$236M	T. Rowe Price, Fidelity Investments & 9 others	71/100
10th	Verve 2018, Cambridge (United States), Acquired	Developer of gene-editing therapies for treating coronary artery disease	$216M	Google Ventures, Wellington & 14 others	70/100
303rd	SomaGenics 1997, Santa Cruz (United States), Funding Raised	Developer of RNA-based therapeutics and diagnosis for multiple disease conditions	-	NIH, HHS	35/100